Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07161843

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Acute Renal Failure (ARF) Acute Kidney Injury Acute Tubular Necrosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Cortex Necrosis Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

10 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Neukidney Inc

Rosharon, Texas, 77583, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized patients
  • presence of Acute renal failure
  • Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of >2%
  • willingness to participate

Exclusion criteria

High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status

Treatment and study plan

QRX-3

Drug

Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Other names: Eseronate

Primary outcomes

  1. Rate of change in creatinine glomerular filtration rate

    Time frame: 28 days

    compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients

Secondary outcomes

  1. daily change in glomerular filtration rate in ml/min

    Time frame: 7 days

    daily change in GFR by creatinine in mls/min

  2. daily change in cystatin C level in mg/dl

    Time frame: 7 days

    daily change in measured cystatin C level

Other outcomes

  1. effect of QRX-3 on recovery of renal function in patients with ATN renal failure

    Time frame: 28

    comparism of number of patient achieving return to baseline renal function in both groups

Study contacts

Contact information is provided by the study sponsor or research team.

Ebima Okundaye, MD

CONTACT

[email protected]

9738855457

Sponsors and collaborators

Lead sponsor

Ebima Clifford Okundaye

Industry

Registry information

Official study title

Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure

Acronym: QRX3 in ARF

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 9, 2025
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.